NZ583120A - Materials and methods for delivering compositions to selected tissues - Google Patents

Materials and methods for delivering compositions to selected tissues

Info

Publication number
NZ583120A
NZ583120A NZ583120A NZ58312008A NZ583120A NZ 583120 A NZ583120 A NZ 583120A NZ 583120 A NZ583120 A NZ 583120A NZ 58312008 A NZ58312008 A NZ 58312008A NZ 583120 A NZ583120 A NZ 583120A
Authority
NZ
New Zealand
Prior art keywords
porous
drug
pores
composition
particles
Prior art date
Application number
NZ583120A
Other languages
English (en)
Inventor
William R Freeman
Michael J Sailor
Lingyun Cheng
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NZ583120A publication Critical patent/NZ583120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25F—PROCESSES FOR THE ELECTROLYTIC REMOVAL OF MATERIALS FROM OBJECTS; APPARATUS THEREFOR
    • C25F3/00—Electrolytic etching or polishing
    • C25F3/02—Etching
    • C25F3/12—Etching of semiconducting materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
NZ583120A 2007-07-10 2008-07-09 Materials and methods for delivering compositions to selected tissues NZ583120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94881607P 2007-07-10 2007-07-10
PCT/US2008/069474 WO2009009563A2 (en) 2007-07-10 2008-07-09 Materials and methods for delivering compositions to selected tissues

Publications (1)

Publication Number Publication Date
NZ583120A true NZ583120A (en) 2012-03-30

Family

ID=40229452

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583120A NZ583120A (en) 2007-07-10 2008-07-09 Materials and methods for delivering compositions to selected tissues

Country Status (9)

Country Link
US (4) US20100196435A1 (enExample)
EP (1) EP2178499B1 (enExample)
JP (3) JP6067207B2 (enExample)
KR (3) KR20100047258A (enExample)
CN (1) CN101815504B (enExample)
AU (1) AU2008275181B2 (enExample)
CA (2) CA2905205A1 (enExample)
NZ (1) NZ583120A (enExample)
WO (1) WO2009009563A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
DK1817003T3 (en) 2004-10-29 2018-05-22 Univ California Porous silicon microparticles for drug delivery to the eye
AU2008275181B2 (en) 2007-07-10 2014-06-26 The Regents Of The University Of California Materials and methods for delivering compositions to selected tissues
CA2751880C (en) 2009-02-10 2017-03-21 Senju Pharmaceutical Co., Ltd. Ring-shaped device
KR101137886B1 (ko) * 2009-04-24 2012-04-25 조선대학교산학협력단 다공성 실리콘 입자를 이용한 영상진단 약물전달체 및 그의 제조방법
CN102405042A (zh) * 2009-05-04 2012-04-04 普西维达公司 多孔硅药物洗脱颗粒
GB201003939D0 (en) * 2010-03-09 2010-04-21 Isis Innovation Multi-spectral scanning system
WO2012005783A1 (en) 2010-07-09 2012-01-12 Board Of Regents Of The University Of Texas System Biodegradable scaffolds
EP2635255B1 (en) * 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
CA2827082A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
FR2972461B1 (fr) * 2011-03-09 2021-01-01 Inst Nat Sciences Appliquees Lyon Procede de fabrication de nanoparticules semi-conductrices
EP2693982B1 (en) * 2011-04-07 2017-08-23 Novartis AG Optical structures with nanostructre features and methods of manufacture
WO2013093631A2 (en) * 2011-12-22 2013-06-27 Nanoco Technologies, Inc. Surface modified nanoparticles
US9708660B2 (en) * 2012-02-19 2017-07-18 Nvigen, Inc. Uses of IDed nanostructures in nucleic acid technology
FR2988721B1 (fr) 2012-03-27 2014-04-04 Centre Nat Rech Scient Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique
GB201301385D0 (en) 2013-01-26 2013-03-13 Chowdhury Dewan F H Particle structures for drug delivery
US20160002272A1 (en) * 2013-02-25 2016-01-07 The Regents Of The University Of California Surface functionalized porous silicon material and method of making thereof
WO2014165108A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
WO2014165097A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Drug delivery device comprising silicon-based carrier particles
RU2705986C2 (ru) * 2013-03-15 2019-11-13 Айпоинт Фармасьютикалз Юэс, Инк. Биоразлагаемые композиции на основе кремния для доставки терапевтических агентов
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3271946A4 (en) * 2015-03-19 2019-12-04 Specmat Inc. SILICULAR SEMICONDUCTOR STRUCTURES, METHOD FOR THE MANUFACTURE THEREOF AND DEVICES THEREWITH
WO2016172769A1 (en) 2015-04-29 2016-11-03 University Of South Australia Compositions and methods for administering antibodies
AU2016291224B2 (en) 2015-07-09 2021-12-23 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
CA3005156C (en) 2015-10-09 2022-11-29 Milwaukee Silicon, Llc Devices and systems for purifying silicon
DE102015121636A1 (de) * 2015-12-11 2017-06-14 Nexwafe Gmbh Vorrichtung und Verfahren zum einseitigen Ätzen einer Halbleiterschicht
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
WO2017181115A1 (en) 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN106729754B (zh) * 2016-12-23 2020-10-23 广州中大南沙科技创新产业园有限公司 三元基因传递系统的冻干制剂及其制备方法
IT201700048421A1 (it) * 2017-05-04 2018-11-04 Materias S R L Dispositivo per la somministrazione transdermica di molecole attive, usi di tale dispositivo e metodi di produzione di tale dispositivo e di relativi componenti
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019191132A1 (en) 2018-03-27 2019-10-03 The Regents Of The University Of California Drug delivery formulations
EP3813908A4 (en) 2018-06-28 2022-04-20 Rand, Kinneret NON-CLOGGING AND ANTI-ADHESIVE MICROCAPILLARY NEEDLE WITH IMPROVED TIP VISIBILITY
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
CN110389131A (zh) * 2019-08-21 2019-10-29 汕头市结核病防治所(汕头市呼吸系疾病防治所) 一种痰液合格验视装置
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
DE102020115925B4 (de) * 2019-12-23 2023-09-07 crop.zone GmbH Verwendung von übergangswiderstandsenkenden Stoffgemischen und Verfahren
US12419517B2 (en) 2020-08-21 2025-09-23 Samsung Electronics Co., Ltd. Nanophotonic sensor implants with 3D hybrid periodic-amorphous photonic crystals for wide-angle monitoring of long-term in-vivo intraocular pressure field
EP4049652A1 (en) * 2021-02-26 2022-08-31 Nano Targeting & Therapy Biopharma Inc. Method for delivering an agent to posterior segment of an eye and uses thereof
US20240180825A1 (en) * 2021-04-20 2024-06-06 The Board Of Trustees Of The Leland Stanford Junior University Polymer Liposome Hydrogel
WO2024249553A1 (en) 2023-05-31 2024-12-05 University Of Tartu Molecules targeting infected tissues and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674743A (en) * 1950-09-21 1954-04-13 Romey A Gaiser Therapeutic, cosmetic, and corrective device
FR1266389A (fr) 1960-09-02 1961-07-07 Jouet simulant le tir d'un avion sur un but à terre ou sur un bateau
US5156896A (en) * 1989-08-03 1992-10-20 Alps Electric Co., Ltd. Silicon substrate having porous oxidized silicon layers and its production method
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
GB9611437D0 (en) * 1995-08-03 1996-08-07 Secr Defence Biomaterial
US6248539B1 (en) 1997-09-05 2001-06-19 The Scripps Research Institute Porous semiconductor-based optical interferometric sensor
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
JP2003516169A (ja) 1999-05-01 2003-05-13 プシメデイカ・リミテツド 誘導多孔性シリコン
GB9909996D0 (en) 1999-05-01 1999-06-30 Secr Defence Brit eland The SEE Sharp Kabushiki Kaisha 3-1 OPTICS - PATENTS 09/06/99 22:40:35 PAGE 40 NUMBER: 5747 30 JUNE 1999 cations For Patents retary of State for Defence, The Derivatized porous silicon
SE9903958D0 (sv) * 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) * 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20030060878A1 (en) * 2001-08-31 2003-03-27 Shadduck John H. Intraocular lens system and method for power adjustment
US7482168B2 (en) * 2001-09-15 2009-01-27 The Regents Of The University Of California Photoluminescent polymetalloles as chemical sensors
US7042570B2 (en) * 2002-01-25 2006-05-09 The Regents Of The University Of California Porous thin film time-varying reflectivity analysis of samples
AU2003208935A1 (en) * 2002-02-07 2003-09-02 The Regents Of The University Of California Optically encoded particles
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
SE522984C2 (sv) 2002-07-25 2004-03-23 Nobel Biocare Ab Anordning vid två eller flera implantat försedda med tillväxtstimulerande substans(-er)
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
US7942989B2 (en) * 2002-12-10 2011-05-17 The Regents Of The University Of California Porous silicon-based explosive
US7713778B2 (en) 2003-02-13 2010-05-11 Univ California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) * 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
WO2005034725A2 (en) 2003-08-14 2005-04-21 The Regents Of The University Of California Photonic sensor particles and fabrication methods
GB0324483D0 (en) * 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
GB2409924A (en) * 2004-01-06 2005-07-13 Psimedica Ltd Method of making a silicon-phosphorus composite
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
KR20040070143A (ko) 2004-07-13 2004-08-06 손영석 하이테크 디지털 다기능의 식탁
WO2006014138A1 (en) * 2004-08-03 2006-02-09 Agency For Science, Technology And Research Polymer having interconnected pores for drug delivery and method
DK1817003T3 (en) * 2004-10-29 2018-05-22 Univ California Porous silicon microparticles for drug delivery to the eye
GB0519391D0 (en) 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
US7527877B2 (en) 2006-10-27 2009-05-05 General Electric Company Platinum group bond coat modified for diffusion control
AU2008275181B2 (en) 2007-07-10 2014-06-26 The Regents Of The University Of California Materials and methods for delivering compositions to selected tissues

Also Published As

Publication number Publication date
JP2010533198A (ja) 2010-10-21
EP2178499A4 (en) 2014-10-22
CA2696139A1 (en) 2009-01-15
US9241906B2 (en) 2016-01-26
AU2008275181A1 (en) 2009-01-15
KR20160021307A (ko) 2016-02-24
US20160338960A1 (en) 2016-11-24
JP2018184427A (ja) 2018-11-22
CA2696139C (en) 2018-04-17
US20200009053A1 (en) 2020-01-09
HK1145652A1 (en) 2011-04-29
JP6368700B2 (ja) 2018-08-01
EP2178499A2 (en) 2010-04-28
CN101815504B (zh) 2013-11-20
US20100196435A1 (en) 2010-08-05
JP2016104748A (ja) 2016-06-09
JP6067207B2 (ja) 2017-01-25
WO2009009563A3 (en) 2009-08-06
US9937129B2 (en) 2018-04-10
KR20170084358A (ko) 2017-07-19
CN101815504A (zh) 2010-08-25
AU2008275181B2 (en) 2014-06-26
WO2009009563A2 (en) 2009-01-15
US20130236518A1 (en) 2013-09-12
EP2178499B1 (en) 2023-11-22
US12171877B2 (en) 2024-12-24
KR20100047258A (ko) 2010-05-07
CA2905205A1 (en) 2009-01-15
WO2009009563A9 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
US12171877B2 (en) Materials and methods for delivering compositions to selected tissues
US11241380B2 (en) Porous photonic crystals for drug delivery to the eye
Cheng et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle
JP2017507158A (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
Shin et al. Noninvasive delivery of self-regenerating cerium oxide nanoparticles to modulate oxidative stress in the retina
HK1145652B (en) Materials and methods for delivering compositions to selected tissues
CN114831930B (zh) 一种胶原蛋白组装眼药、制备方法及应用
Patel et al. Formulation and evaluation of sustained release ocular drug delivery system for an anti-glaucoma drug
Stoia et al. Multifunctional Polymeric Microspheres for Targeted Delivery and NIR-Light Stimulated Release of the Therapeutic
Desmettre et al. Propriétés de fluorescence et particularités métaboliques de la fluorescéine
Wang Drug Delivery, Imaging and Sensing using Porous Silicon Materials
Muirhead Ophthalmic Biomaterials
Wu Sustained and observable release of therapeutics using porous silicon based materials

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2016 BY COMPUTER PACKAGES INC

Effective date: 20150618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2017 BY COMPUTER PACKAGES INC

Effective date: 20160618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2018 BY COMPUTER PACKAGES INC

Effective date: 20170620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2019 BY COMPUTER PACKAGES INC

Effective date: 20180619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2020 BY COMPUTER PACKAGES INC

Effective date: 20190618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2021 BY COMPUTER PACKAGES INC

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2022 BY COMPUTER PACKAGES INC

Effective date: 20210617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2023 BY COMPUTER PACKAGES INC

Effective date: 20220618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2024 BY COMPUTER PACKAGES INC

Effective date: 20230617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2025 BY COMPUTER PACKAGES INC

Effective date: 20240617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2026 BY NICK CUNNINGHAM

Effective date: 20250701